Navigation Links
Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
Date:11/5/2007

CHARLOTTE, N.C., Nov. 5 /PRNewswire-FirstCall/ -- MedCath Corporation (Nasdaq: MDTH) announced today that Arizona Heart Hospital, one of the 11 hospitals in which MedCath owns an interest, has entered into a settlement with the United States Department of Justice (the DOJ) and the United States Attorneys' Office in Phoenix under the federal Civil False Claims Act.

The settlement concerns Medicare claims submitted between June 1998 and October 2002 for physician services involving the implantation of certain endoluminal graft devices (utilized to treat aneurysms) that had not received final marketing approval from the Food and Drug Administration, and allegedly were either implanted without an approved investigational device exception (IDE) or were implanted outside of the approved IDE protocol. The DOJ's allegations related solely to whether the procedures were properly reimbursable by Medicare; quality of patient care was not at issue.

The parties reached a settlement of the allegations to avoid the delay, uncertainty, inconvenience, and expense of protracted litigation. Further, the hospital denies engagement in any wrongdoing or illegal conduct, and the settlement agreement does not contain any admission of liability. As previously disclosed in MedCath's filings with the Securities and Exchange Commission, the hospital will pay approximately $5.8 million to settle and obtain a release from any civil or administrative monetary claims related to the DOJ's investigation. Additionally, the hospital has entered into a five- year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services under which the hospital will continue to maintain its existing
'/>"/>

SOURCE MedCath Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
2. Many Heart Attack Patients Dont Get Best Emergency Treatment
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
11. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...VYVANSE demonstrated significant improvement in AD...ire-FirstCall/ -- Shire plc (LSE: SHP,Nasdaq: SHP...y, today,presented the results of a phase III pivo...t improvements in Attention Deficit Hyperactivity,...ety and efficacy,endpoints., "Adults with ADHD of...
(Date:5/8/2008)... Treatment Provides "Blueprint" to Produce Therap..., Ill., May 8 /PRNewswire-USNewswire/ -- Using gen...fighting proteins through,skin flaps placed on can...in tumor volume, according to a study in the May i... official medical journal of the American,Society ...
(Date:5/8/2008)...- Memorial Sloan-Kettering Cancer Center Investiga...egative Ovarian Cancer Patients -, BRISBANE, Cali...ay,announced the expansion of Phase 2 clinical tri...ian cancer. This is the third major clinical trial...months, expanding on,on-going trials in breast and...
(Date:5/7/2008)...nternational Study to Evaluate Efficacy and Safety...ause of Blindness, LEVERKUSEN, Germany, MONTVILLE...swire-FirstCall/ -- Bayer HealthCare AG and Regene...nnounced that the first patient,has been dosed in ...in a,development program evaluating VEGF Trap-Eye ...
Breaking Medicine Technology:Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 3Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 4Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 5Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 6Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 1Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 2Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 3Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 4Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 5Vical Reports Second Quarter 2007 Financial Results Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 66 6Wyeths Torisel and Roche Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell 61 1Wyeths Torisel and Roche Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell 61 2Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL Carrier of Good Cholesterol 56 1Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL Carrier of Good Cholesterol 56 2Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL Carrier of Good Cholesterol 56 3Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 51 1Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 51 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 51 3
...-FirstCall/ --,Citing issues related to potentiall...nor Medsystems, LLC has concluded that the COSTAR,...or Restenosis),trial, the pivotal study for the Co...tent, failed to meet its primary,endpoint. The tri...,rates of death, myocardial infarction and stent t...
.../ - Isotechnika Inc.,today announced the audited t...g Committee, of the first third of the patients,tr...ial for the,Company,s lead immunosuppressive drug,... assessment of the first,116 patients enrolled. Th...e (0.4 mg/kg twice daily) resulting in 11% inciden...
Other Medicine Technology:Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 2Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 3Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 4Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 2Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 3Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 4Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 5
(Date:5/9/2008)...ire/ -- OxyBand Technologies, Inc. today,announced...tes Army to,evaluate the company,s patented cuttin...d other military wounds. OxyBand Technologies has ...rs pure oxygen gas into wounds for,faster healing....rials to,accelerate healing and, in laboratory tes...
(Date:5/9/2008)... Supply Flights en Route, NEW YORK, May 9 /PRNews...UNICEF emergency supplies landed in Yangon today, ... Three more planeloads containing,medicines, emerg...,children, are planned over the next three days., ...second can make a,difference in the life of a Myan...
(Date:5/9/2008)...fixture of European nightlife, study says , ... and young adults in Europe are drinking alcohol a...a survey of more than 1,300 people who are regular...third of males and a quarter of females aged 16 to..., while cocaine, ecstasy and cannabis are used to ...
(Date:5/9/2008)...d by the artery-opening devices , , FRID... cornerstone of heart-disease treatment, tiny tool...ents by maintaining the flow of blood through thei...nserted following artery-clearing angioplasty proc...tant supply of blood to the heart and throughout t...
Breaking Medicine News(10 mins):Health News:OxyBand Technologies Signs Army Contract 2Health News:UNICEF: 'Every Second Can Make a Difference' to Myanmar's Children; 20% Already Suffering from Diarrhea, Malaria reported 2Health News:UNICEF: 'Every Second Can Make a Difference' to Myanmar's Children; 20% Already Suffering from Diarrhea, Malaria reported 3Health News:Young Adults Using Alcohol, Drugs for Better Sex 2Health News:Drug-Coated Stents Still Spark Debate 2Health News:Drug-Coated Stents Still Spark Debate 3
...quent ventricular ectopy, another name for prematu...been found by researchers to be a better predictor... during exercise. Doctors from Cleveland Clinic Fo...y of heart failure, valve disease or arrhythmia. T...
...amin C has been believed, over the years, to be a ... has now been proved to be true by researchers who... vitamin C. The researchers reported that in their...f vitamin C a day for two weeks, they found a boos...
... New Scientist magazine in its January issue has r...burgers, fries and foods high in fat and calories ...eating oneself to obesity is not just due to a lac... hormonal changes caused by the fast foods, in the...
...hn's disease is an often debilitating, lifelong ga...people are in their 20s or 30s. The disease leaves... or it causes severe abdominal pain. However, trea...ts suffering from the disease. Now, Dr. Brian Diec...
Other Medicine News:
Increased volume for use with 4, 8, or 12 channel pipettors. Angled sides and V-shaped bottom permits withdrawal of nearly all of the solution. Corners have pouring lips to dispose of excess solution
Volume: 2 ml; Volume Graduation: 1/100 ml
... use with measuring pipettes, enables you to pipet.... It works with all types of glass or plastic pipe...ns Pipette Aid is equipped with a safety valve and...echanism of the device from contamination by the v...
The Finnpipette BioMate pipetting aid excels when it comes to precise pipetting. The aspirate/dispense speed can be easily selected using the speed-setting slide switch. The powerful pump quickly fil
Medicine Products: